For a new tuberculin skin test (TST) to be considered useful, it must meet several requirements including safety, a readable skin response, affordability, a high predictive value, and it cannot easily sensitize, depend on patient characteristics, nor depend on the Mycobacterium tuberculosis isolate. After review of previously conducted animal model studies, we designed a doubleblind randomized Phase 1 study comparing recombinant dimer ESAT-6 (rdESAT-6, Statens Serum Institut, Copenhagen, Denmark) to tuberculin as a skin test reagent in the diagnosis of TB. The goals of the study were to assess the safety of an intradermal method of administering the test and to determine the appropriate human dose. The study compared the administration of 2.0 TU PPD (standard dose of RT 23) to four doses of rdESAT-6 (0.01, 0.1, 1, and 10μg). The protocol also called for intra-subject randomization of the left and right forearm. Participants were enrolled in eight different groups. Four groups comprised five healthy controls each for the purpose of testing safety and sensitization issues. The other four groups comprised patients who had been treated for TB in order to determine safety and optimal dose. Several exclusion criteria were applied, including individuals who had received a TST test within the past year or had a known immune deficiency. During the 28-day trial, the guidelines called for 2 hours of close observation after administering the test on Day 0; clinical parameters, photography on Days 1 to 4 with quantiFERON testing of control subjects on Day 2 and lab and urine tests on Day 4; diary keeping on Days 5 to 28 with physical exam, lab and urine tests on Day 28 and quantiFERON testing of control groups.
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In control groups, all four dosages of rdESAT-6 were administered with no serious side effects; transient redness occurred at 24 hours at the 10 μg dose; and no indication of sensitization was measured in vitro. In the treated TB group, only doses of 0.01 and 0.1 of rdESAT-6 were well-tolerated; equivalent responses to PPD and 0.1 μg rdESAT-6 were observed. Participants reported significant local side effects at 1 μg of rdESAT-6. Results indicate that the new skin test is safe, produced a readable skin test response, did not easily sensitize, and is robust in all practical aspects. Further studies must be conducted on subjects ranging from individuals with active and latent TB, children, pregnant women, and patients who are immunocompromised.
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